ArtVentive Medical Group, Inc. (OTC Bulletin Board:AVTD) announced today that the Company has entered into a strategic agreement with the internationally renowned regulatory, clinical and quality assurance group, Northwest Clinical Research Group, Inc. (NCRG). NCRG has over 50 years of combined global experience in regulatory affairs, clinical research and quality systems development within the medical device field. This agreement between the two companies will assist ArtVentive Medical Group, Inc. in building its quality systems, regulatory strategy, and securing FDA and European approvals in a timely manner. NCRG offers comprehensive services that include, but are not limited to, cardiovascular, endovascular, neurology, pulmonary, and orthopedic areas of healthcare with extensive expertise in clinical studies around the world, IDEs within the USA, and CE Mark in Europe.

?Entering into this agreement with NCRG has already had a positive impact on our timing for European and FDA approvals? said Jim Graham, President of ArtVentive Medical Group, Inc., ?This Agreement is essential in achieving the Company's goal towards regulatory approval and puts us one step closer to getting our products to market quickly.? Graham further reported that Northwest Clinical Research Group is providing a full platform of quality controls to solidify those already in place.

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in San Marcos, California, is an innovative, multi faceted medical device corporation, focused on developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).

ArtVentive Medical Group, Inc., through its proprietary technology has developed unique minimally invasive occlusion devices and procedures, bringing the current interventional image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues. The EOS device developed by ArtVentive Medical Group targets a substantive market demand in several major clinical areas, including women's health, peripheral and neurological vascular disorders, and interventional cardiology procedures. The EOS is a catheter based self-expandable device, serving for permanent or temporary (reversible) occlusion of body lumens. The patented revolutionary device will serve in many cases as a safe and reliable alternative to major surgery.

Forward-Looking Statements

This news release may include "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, These statements are based on the beliefs by our management as well as assumptions made by and information currently available to the company. These statements reflect the company's current views with respect to future events and are not guarantees of future performance. These statements may involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the said forward-looking statements. These factors include, among other things, the company's periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. Except as required by law, the company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the company's filings with the Securities and Exchange Commission which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States.

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, President
760-471-7700
hjgraham@artventivemedical.com